There are very few shares out which is very positive for shareholders. I do understand why companies stop creating audited financials and staying current. There is a big cost here and the money can be used for further developing their stem cell line. It is a conscious decision that many companies make. A company can always catch up their filings when their business picks up.
As for their topical, could be a great product but it would be better is it could be purchased over the counter - but marketing expenses... can be large. So start with clinics that provide other beauty services such as Botox... Maybe over the counter or an infomercial at a later time.
I am concerned that their IND for AlloRx Stem Cell(R) Therapy for covid has not been approved yet. This was submitted back in April. Seems like anything associated to covid-19 is approved quickly. Do you know if they are ready or can afford to pursue p1? This is the biggest product they have from what I can tell.
Have a good weekend and hope I woke this board up.
News 
Market Data 
Discover 
AI
